Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 3/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | TK2 | O00142 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8027668 | 0.91 | RNASE1 (0.41) | RNASE1TK1TYMSTK2 | |
| SCHEMBL2594578 | 0.89 | RNASE1 (0.42) | RNASE1TK1TK2 | |
| SCHEMBL2710682 | 0.89 | RNASE1 (0.42) | RNASE1 | |
| SCHEMBL6232615 | 0.89 | RNASE1 (0.42) | RNASE1TK1TYMSTK2TYMP | |
| SCHEMBL6324546 | 0.88 | RNASE1 (0.45) | RNASE1TK1TYMSTK2TYMP | |
| SCHEMBL6830784 | 0.87 | RNASE1 (0.39) | RNASE1TK1TK2 | |
| SCHEMBL6735623 | 0.86 | RNASE1 (0.41) | RNASE1TK1TYMSTK2TYMP | |
| SCHEMBL8034055 | 0.84 | RNASE1 (0.40) | RNASE1TK1TYMSTK2TYMP | |
| SCHEMBL6830104 | 0.84 | TK1 (0.34) | RNASE1TK1TK2TYMP | |
| SCHEMBL15302164 | 0.84 | TYMP (0.46) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023310-B2 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-7723511-B2 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080293929-A1 | SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7378516-B2 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7273933-B1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7227015-B2 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060069248-A1 | Process for producing phosphoroamidite | MITSUI CHEMICALS, INC. (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1582528-A1 | PROCESS FOR PRODUCING PHOSPHOROAMIDITE | Mitsui Chemicals, Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-20050165226-A1 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS INC. | 2005-07-28 | — | — | US | disclosed |
| US-6846922-B1 | Reacting phosphoramidite with hydroxyl group of nucleoside or oligonucleotide linked to solid support in presence of activating reagent comprising at least one pyridinium salt and at least one substituted imidazole | ISIS PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-6399831-B1 | THIODICARBONIC ACID DIESTER POLYSULFIDE | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6274725-B1 | PROVIDING COMPOUND HAVING A HYDROXYL GROUP; REACTING WITH PHOSPHITYLATING REAGENT IN THE PRESENCE OF A PYRIDINUM SALT IN A SOLVENT UNDER CONDITIONS OF TIME, TEMPERATURE AND PRESSURE TO YIELD PHOSPHITYLATED COMPOUND | ISIS PHARMACEUTICALS, INC. | 2001-08-14 | — | — | US | disclosed |
| WO-2001051502-A1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6242591-B1 | Synthesis of sulfurized 2'-substituted oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| US-6114519-A | PHOSPHITYLATION; OXIDATION ACYL DISULFIDE | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-6040438-A | Reagent useful for synthesizing sulfurized oligonucleotide analogs | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-5902881-A | Reagent useful for synthesizing sulfurized oligonucleotide analogs | ISIS PHARMACEUTICALS, INC. (US) | 1999-05-11 | — | — | US | disclosed |
| US-5866691-A | Lactam nucleic acids | ISIS PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5714597-A | Use of carbocation scavenger during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5510476-A | SOLID PHASE SYNTHESIS USING AN ACIDIC SOLUTION OF THE SCAVENGER TO DEPROTECT THE 5'-HYDROXY AND NEUTRALIZE THE CARBO ANION RELEASED; HIGH YIELDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069248-A1 | Process for producing phosphoroamidite | PPA1, ITPA, MTAP | RNASE1 1227/4885TK1 252/4885TYMS 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.